Amanote Research
Register
Sign In
PD-L1 Upregulation Drives Escape From Anti-Ctla4 and Radiation Therapy
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2015-049
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
March 19, 2015
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
KRAS Mutation-Induced Upregulation of PD-L1 Mediates Immune Escape in Human Lung Adenocarcinoma
Cancer Immunology, Immunotherapy
Cancer Research
Medicine
Oncology
Allergy
Immunology
Macrophage PD-L1 Strikes Back: PD-1/PD-L1 Interaction Drives Macrophages Toward Regulatory Subsets
Advances in Bioscience and Biotechnology
Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment
International Journal of Clinical Oncology
Medicine
Surgery
Oncology
Hematology
Prostate Cancer Responds to Anti–PD-1–ctla4 Combo
Cancer Discovery
Oncology
Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy
Oncolytic Virotherapy
Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-γ by Anti-Pd-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma Bovis Infection
Frontiers in Veterinary Science
Veterinary
The Efficacy and Safety of Anti-Pd-1/Pd-L1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First-Line Treatment for Advanced Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
Long-Term Survival in Patients Responding to Anti-Pd-1/Pd-L1 Therapy and Disease Outcome Upon Treatment Discontinuation
Clinical Cancer Research
Cancer Research
Oncology
CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients
JCI insight
Medicine
